PURA - Puration Announces Analyst Update Report Coming Thursday February 28, 2019
February 26 2019 - 12:01PM
InvestorsHub NewsWire
PURA - Puration Announces Analyst
Update Report Coming Thursday February 28, 2019
Dallas, TX -- February 26, 2019 --
InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) today announced an upcoming analyst update report
expected to be published this Thursday, February 28, 2019.
The report expected on Thursday will be a second update from
Goldman Small Cap Research which initiated analyst coverage in
October last year and published a first update in November of last
year confirming a Speculative Buy and $0.25 Target
PPS. The company has since the first update signed
additional contracts and launched an all new formulation and
packaging of its EVERx CBD Sports Water. Earlier today, the
company previewed a major coming announcement regarding
its EVERx CBD Sports Water planned for release later this week. The
previewed announcement expected later this week is separate from
the Analyst Report update planned for release on Thursday this
week. The update report is anticipated to include an
assessment of PURA’s $1.5 million contract with Generex
Biotechnology (USOTC:
GNBT) to produce custom, private ladled, CBD Infused water for
Generex. PURA is working with Kali-Extracts (USOTC:
KALY) to develop the customer CBD extract formulation for
infusion into the water produced for
Generex.
For more information on Puration,
visit http://www.purationinc.com
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Apr 2023 to Apr 2024